Safety Study of Apixaban in Recent Acute Coronary Syndrome

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Apixaban

Criteria

Key Inclusion Criteria:

• Recent (< = 7 days) Acute Coronary Syndrome (ACS).

• Clinically stable on optimal treatment

Key Exclusion Criteria:

• High bleeding risk.

• Ongoing anticoagulant use.

• Need for chronic (>3 months) daily nonsteroidal anti-inflammatory drug (NSAID) or chronic high dose acetylsalicylic acid (ASA) use (>325 mg/day